GW jumps on Phase IIa schizophrenia data

GW Pharmaceuticals plc (LSE:GWP; NASDAQ:GWPH) gained $8.10 (8%) to $115 on Tuesday after reporting data from an exploratory Phase IIa proof-of-concept trial of oral cannabidiol ( GWP42003) in patients with schizophrenia.

The trial's 88 patients were previously treated with first-line anti-psychotics and continued on their treatment regimens while receiving an oral liquid formulation of cannabidiol or placebo as adjunct therapy for six weeks. Cannabidiol is a phytocannabinoid found in Cannabis sativa. ...